Pacira BioSciences (PCRX) Short Interest Ratio & Short Volume $19.75 -0.08 (-0.40%) (As of 10:26 AM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Pacira BioSciences Short Interest DataPacira BioSciences (PCRX) has a short interest of 4.80 million shares. This marks a -0.41% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.0, indicating that it would take 6.0 days of the average trading volume of 847,348 shares to cover all short positions.Current Short Interest4,800,000 sharesPrevious Short Interest4,820,000 sharesChange Vs. Previous Month-0.41%Dollar Volume Sold Short$81.17 millionShort Interest Ratio6.0 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares46,173,000 sharesPercentage of Shares Shorted10.40%Today's Trading Volume45,883 sharesAverage Trading Volume847,348 sharesToday's Volume Vs. Average5% Short Selling Pacira BioSciences? Sign up to receive the latest short interest report for Pacira BioSciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPCRX Short Interest Over TimePCRX Days to Cover Over TimePCRX Percentage of Float Shorted Over Time Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Pacira BioSciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/20244,800,000 shares $81.17 million -0.4%N/A6 $16.91 11/15/20244,820,000 shares $80.01 million -11.7%N/A6.2 $16.60 10/31/20245,460,000 shares $90.64 million -11.1%N/A5.3 $16.60 10/15/20246,140,000 shares $102.48 million -2.7%N/A5.3 $16.69 9/30/20246,310,000 shares $94.97 million +9.7%N/A5 $15.05 9/15/20245,750,000 shares $75.38 million -5.0%N/A4 $13.11 Get the Latest News and Ratings for PCRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. 8/31/20246,050,000 shares $94.14 million +17.5%N/A4.5 $15.56 8/15/20245,150,000 shares $68.75 million -18.4%N/A4 $13.35 7/31/20246,310,000 shares $130.30 million -2.9%N/A5.3 $20.65 7/15/20246,500,000 shares $138.45 million -3.4%N/A6.2 $21.30 6/30/20246,730,000 shares $192.55 million +5.8%N/A7.2 $28.61 6/15/20246,360,000 shares $178.91 million -1.1%N/A8.8 $28.13 5/31/20246,430,000 shares $195.02 million +6.5%N/A9.9 $30.33 5/15/20246,040,000 shares $181.68 million +67.8%N/A9.4 $30.08 4/30/20243,600,000 shares $94.50 million +4.4%N/A6.7 $26.25 4/15/20243,450,000 shares $91.53 million -7.8%N/A7 $26.53 3/31/20243,740,000 shares $109.28 million -8.1%N/A7.5 $29.22 3/15/20244,070,000 shares $119.70 million -2.4%N/A8.1 $29.41 2/29/20244,170,000 shares $123.93 million +5.8%N/A7.4 $29.72 2/15/20243,940,000 shares $116.86 million +1.0%N/A7.4 $29.66 1/31/20243,900,000 shares $127.10 million +4.6%N/A6.9 $32.59 1/15/20243,730,000 shares $120.18 million +6.9%N/A7 $32.22 12/31/20233,490,000 shares $117.75 million +7.4%N/A6.5 $33.74 12/15/20233,250,000 shares $101.69 million -0.9%N/A5.8 $31.29 11/30/20233,280,000 shares $89.48 million +2.8%N/A6.7 $27.28 11/15/20233,190,000 shares $91.11 million -11.1%N/A6.4 $28.56 10/31/20233,590,000 shares $101.45 million -8.7%N/A7.5 $28.26 10/15/20233,930,000 shares $114.52 million +12.0%N/A7.7 $29.14 9/30/20233,510,000 shares $107.69 million -0.3%N/A6.5 $30.68 9/15/20233,520,000 shares $118.41 million -1.4%N/A6.8 $33.64 8/31/20233,570,000 shares $126.02 million -4.8%N/A6.3 $35.30 8/15/20233,750,000 shares $139.91 million +9.7%N/A6.6 $37.31 7/31/20233,420,000 shares $124.32 million -3.4%N/A5.9 $36.35 7/15/20233,540,000 shares $132.01 million -2.5%N/A6 $37.29 6/30/20233,630,000 shares $145.45 million -0.6%N/A6.3 $40.07 6/15/20233,650,000 shares $147.17 million +3.7%N/A6.6 $40.32 5/31/20233,520,000 shares $133.87 million +4.5%N/A6.6 $38.03 5/15/20233,370,000 shares $143.12 million +7.7%N/A5.9 $42.47 4/30/20233,130,000 shares $141.82 million +4.0%N/A5.4 $45.31 4/15/20233,010,000 shares $127.77 million No ChangeN/A5.5 $42.45Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover 3/31/20233,010,000 shares $122.84 million -10.4%N/A5.6 $40.81 3/15/20233,360,000 shares $132.25 million -5.9%N/A6.1 $39.36 2/28/20233,570,000 shares $151.97 million No ChangeN/A6.1 $42.57 2/15/20233,570,000 shares $144.91 million -20.7%N/A6.6 $40.59 1/31/20234,500,000 shares $176.72 million -12.8%N/A8.6 $39.27 1/15/20235,160,000 shares $193.09 million +4.2%N/A9.9 $37.42 12/30/20224,950,000 shares $191.12 million +7.1%N/A9.9 $38.61 12/15/20224,620,000 shares $184.38 million -6.3%N/A10.1 $39.91 11/30/20224,930,000 shares $237.87 million -10.5%N/A12.6 $48.25 11/15/20225,510,000 shares $275.50 million +0.7%N/A14.4 $50.00 10/31/20225,470,000 shares $283.13 million +1.7%N/A15.3 $51.76 10/15/20225,380,000 shares $277.61 million +4.3%N/A15.3 $51.60 9/30/20225,160,000 shares $274.46 million +2.2%N/A13.9 $53.19 9/15/20225,050,000 shares $274.06 million +4.3%N/A12.7 $54.27 8/31/20224,840,000 shares $254.00 million +3.9%N/A11.3 $52.48 8/15/20224,660,000 shares $269.02 million +1.8%N/A10.7 $57.73 7/31/20224,580,000 shares $259.04 million -0.2%N/A9.7 $56.56 7/15/20224,590,000 shares $252.45 million +5.8%N/A9.2 $55.00 6/30/20224,340,000 shares $253.02 million -12.9%N/A8.3 $58.30 6/15/20224,980,000 shares $271.66 million -3.1%12.5%9.4 $54.55 5/31/20225,140,000 shares $325.11 million +0.2%N/A9.9 $63.25 5/15/20225,130,000 shares $315.75 million -3.9%N/A9.2 $61.55 4/30/20225,340,000 shares $398.20 million +3.5%N/A9.5 $74.57 4/15/20225,160,000 shares $385.35 million -8.0%11.8%9.3 $74.68 3/31/20225,610,000 shares $428.16 million -3.3%12.9%10.3 $76.32 3/15/20225,800,000 shares $409.42 million -7.9%13.3%11.6 $70.59 2/28/20226,300,000 shares $420.15 million -4.8%14.4%12 $66.69 2/15/20226,620,000 shares $428.58 million -1.1%15.3%13.3 $64.74 1/31/20226,690,000 shares $419.93 million +5.2%15.4%13.5 $62.77 1/15/20226,360,000 shares $407.55 million -6.5%14.7%13.2 $64.08 12/31/20216,800,000 shares $409.16 million -0.2%15.7%14.5 $60.17 12/15/20216,810,000 shares $392.05 million -0.7%15.7%13.1 $57.57 11/30/20216,860,000 shares $360.97 million +4.9%15.8%13.8 $52.62 11/15/20216,540,000 shares $366.17 million -3.8%15.1%14.3 $55.99 10/29/20216,800,000 shares $355.50 million +3.8%15.7%15 $52.28 10/15/20216,550,000 shares $348.46 million -5.4%15.1%14.8 $53.20 9/30/20216,920,000 shares $387.52 million -3.4%16.0%16.4 $56.00 9/15/20217,160,000 shares $395.09 million +5.6%16.5%20.6 $55.18 8/31/20216,780,000 shares $401.99 million +1.8%15.6%17.6 $59.29 8/13/20216,660,000 shares $388.41 million -1.3%15.4%17 $58.32 7/30/20216,750,000 shares $397.91 million -2.7%15.6%16.1 $58.95 7/15/20216,940,000 shares $389.13 million +3.1%16.2%16.4 $56.07 6/30/20216,730,000 shares $408.38 million -4.3%15.7%14.9 $60.68 6/15/20217,030,000 shares $419.55 million -0.9%16.4%15.3 $59.68 5/28/20217,090,000 shares $430.15 million +1.9%16.5%16.2 $60.67 5/14/20216,960,000 shares $427.76 million -2.8%N/A16.3 $61.46 4/30/20217,160,000 shares $459.67 million -0.3%N/A16.6 $64.20 4/15/20217,180,000 shares $498.51 million -3.5%N/A15.9 $69.43 3/31/20217,440,000 shares $526.90 million +5.5%N/A15.4 $70.82 3/15/20217,050,000 shares $517.96 million +4.4%N/A14.6 $73.47Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover 2/26/20216,750,000 shares $502.54 million +13.8%N/A13.8 $74.45 2/12/20215,930,000 shares $466.69 million -4.8%N/A12 $78.70 1/29/20216,230,000 shares $416.97 million -5.2%N/A12.5 $66.93 1/15/20216,570,000 shares $506.94 million -6.8%N/A13.5 $77.16 12/31/20207,050,000 shares $413.91 million +13.5%N/A15.4 $58.71 12/15/20206,210,000 shares $365.77 million +8.8%N/A14.5 $58.90 11/30/20205,710,000 shares $364.30 million -3.9%N/A12.9 $63.80 11/15/20205,940,000 shares $378.02 million -2.6%N/A13.5 $63.64 10/30/20206,100,000 shares $324.03 million +5.5%N/A13.6 $53.12 10/15/20205,780,000 shares $335.47 million +1.9%N/A11.2 $58.04 9/30/20205,670,000 shares $340.88 million -8.7%N/A10.4 $60.12 9/15/20206,210,000 shares $367.69 million -3.0%N/A8.6 $59.21 8/31/20206,400,000 shares $400.13 million -11.4%N/A8.9 $62.52 8/14/20207,220,000 shares $442.08 million -11.2%N/A9.6 $61.23 7/31/20208,130,000 shares $427.72 million +1.0%N/A10.7 $52.61 7/15/20208,050,000 shares $445.41 million +23.9%N/A11.3 $55.33 6/30/20206,500,000 shares $341.06 million +18.2%N/A9 $52.47 6/15/20205,500,000 shares $238.76 million +3.2%N/A9 $43.41 5/29/20205,330,000 shares $234.25 million +1.1%N/A7.3 $43.95 5/15/20205,270,000 shares $212.28 million +1.9%N/A7.1 $40.28 4/30/20205,170,000 shares $213.47 million +11.9%N/A7 $41.29 4/15/20204,620,000 shares $164.01 million +16.7%N/A6.6 $35.50 3/31/20203,960,000 shares $157.57 million -8.6%N/A5.7 $39.79 3/13/20204,332,500 shares $154.63 million -2.4%N/A4.9 $35.69 2/28/20204,440,000 shares $126.10 million +0.5%N/A8.4 $28.40 2/14/20204,420,000 shares $163.10 million -0.7%N/A8.7 $36.90 1/31/20204,450,000 shares $200.87 million +7.0%11.0%9.2 $45.14 1/15/20204,160,000 shares $207.92 million +10.9%10.3%8.7 $49.98 12/31/20193,750,000 shares $164.29 million +0.8%9.3%7.8 $43.81 PCRX Short Interest - Frequently Asked Questions What is Pacira BioSciences' current short interest? Short interest is the volume of Pacira BioSciences shares that have been sold short but have not yet been covered or closed out. As of November 30th, investors have sold 4,800,000 shares of PCRX short. Learn More on Pacira BioSciences' current short interest. What is a good short interest ratio for Pacira BioSciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PCRX shares currently have a short interest ratio of 6.0. Learn More on Pacira BioSciences's short interest ratio. Which institutional investors are shorting Pacira BioSciences? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Pacira BioSciences: Parallax Volatility Advisers L.P., Sio Capital Management LLC, Walleye Trading LLC, and Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Pacira BioSciences' short interest increasing or decreasing? Pacira BioSciences saw a decrease in short interest during the month of November. As of November 30th, there was short interest totaling 4,800,000 shares, a decrease of 0.4% from the previous total of 4,820,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Pacira BioSciences' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Pacira BioSciences: Perrigo Company plc (2.95%), Supernus Pharmaceuticals, Inc. (12.20%), Omeros Co. (16.11%), Nektar Therapeutics (2.49%), Assembly Biosciences, Inc. (0.36%), Cumberland Pharmaceuticals Inc. (2.09%), Eli Lilly and Company (0.69%), Johnson & Johnson (0.77%), AbbVie Inc. (1.09%), Merck & Co., Inc. (1.30%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Pacira BioSciences stock? Short selling PCRX is an investing strategy that aims to generate trading profit from Pacira BioSciences as its price is falling. PCRX shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Pacira BioSciences? A short squeeze for Pacira BioSciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PCRX, which in turn drives the price of the stock up even further. How often is Pacira BioSciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PCRX, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies Perrigo Short Interest Data Supernus Pharmaceuticals Short Interest Data Omeros Short Interest Data Nektar Therapeutics Short Interest Data Assembly Biosciences Short Interest Data Cumberland Pharmaceuticals Short Interest Data Eli Lilly and Company Short Interest Data Johnson & Johnson Short Interest Data AbbVie Short Interest Data Merck & Co., Inc. Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PCRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
